CVS Health delivered strong Q4 2025 results with revenue exceeding $105 billion (+8% YoY) and adjusted EPS of $1.09, capping a year of significant operational progress. For the full year, the company reported adjusted EPS of $6.75, beating initial expectations by approximately 15%, and operating cash flow of $10.6 billion. The Aetna insurance segment demonstrated a dramatic turnaround with a year-over-year adjusted operating income improvement of over $2.6 billion, while the Pharmacy & Consumer Wellness segment exceeded expectations with same-store script growth of over 19%. Despite reaffirming confident 2026 guidance for adjusted EPS of $7.00-$7.20, management acknowledged headwinds from the proposed 2027 Medicare Advantage rates, which they stated do not match current medical cost trends.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | >$105 billion | +8% YoY |
| Q4 Adjusted EPS | $1.09 | Modest decline YoY |
| FY 2025 Adjusted EPS | $6.75 | +15% vs initial expectations |
| FY 2025 Operating Cash Flow | $10.6 billion | Meaningful outperformance |
| Aetna Adj. Op Income Improvement | >$2.6 billion | YoY Increase |
| Same-store Script Growth | >19% | Q4 YoY |
| Leverage Ratio | ~4.0x | Improvement from prior year |
Aetna Turnaround Execution: The most significant strategic signal is the successful execution of the Aetna turnaround, with adjusted operating income improving by over $2.6 billion year-over-year in 2025. Management stated they are 'laser-focused on improving margins' and expect 2026 to be another 'strong step forward on our path to target margins.' This indicates that the core insurance risk is abating and the segment is returning to being a reliable profit engine.
PBM Value Proposition Under Fire: CVS is aggressively defending its PBM model against regulatory and political pressure by framing it as the primary check against pharmaceutical inflation. CEO Joyner highlighted that brand manufacturers added '$25 billion of cost to the health care system' in early 2026 alone, positioning Caremark as the essential negotiator creating '$45 billion of annual savings.' This signals a strategic shift towards transparency (TrueCost) to align with legislative trends while protecting margins.
Retail Stabilization and Growth: The Pharmacy & Consumer Wellness segment has established a 'new trajectory of at least flat earnings annually starting in 2026' following the successful completion of the CostVantage transition to cost-based reimbursement. With same-store prescription volumes up nearly 10% and retail script share growing to over 29%, the retail asset is proving to be a durable component of the enterprise ecosystem rather than a divestiture candidate.
Vertical Integration as a Moat: Management heavily emphasized the competitive advantage of their 'connected solution,' citing specific examples like Aetna members having lower medical costs when using CVS pharmacies and the ability to drive 96% adoption of low-cost biosimilars. This signals that the 'power of the combined enterprise' is the core investment thesis, allowing them to leverage data and scale to lower total cost of care in ways competitors cannot replicate.
Medicare Advantage 2027 Rate Shock: The proposed 2027 Medicare Advantage advance rate notice was described as 'disappointing' and failing to match medical cost trends. While management claims their commitment to margin recovery is 'unchanged' and it won't impact the long-term enterprise guide, the rates being 'simply not adequate' poses a tangible risk to 2027 earnings growth and may require more aggressive cost controls or pricing actions than currently modeled.
Elevated Medical Costs and Q4 Losses: Despite the annual improvement, the Health Care Benefits segment posted an adjusted operating loss of $676 million in Q4, driven by 'deterioration of our risk adjustment position' and a provision for flu activity. Management noted medical cost trends remained 'elevated across all products,' suggesting that the underwriting gains in 2025 could be fragile if utilization remains high or flu seasons remain severe.
Membership Erosion: Total medical membership declined by approximately 500,000 year-over-year to 26.6 million, driven by losses in Individual Exchange and Government businesses. While commercial fee-based membership grew, the decline in government lines (Medicare/Medicaid) restricts top-line growth potential and raises questions about the competitiveness of their product offerings in a price-sensitive market.
Cash Flow Volatility: While 2025 operating cash flow was strong at $10.6 billion, guidance for 2026 was updated to 'at least $9 billion,' a decrease that management attributes to timing shifts in payments. This highlights the sensitivity of their cash conversion cycle to regulatory changes and payment mechanics, creating potential volatility in free cash flow that could impact deleveraging timelines or share repurchase flexibility.
Overall: Management exhibited a confident and assertive demeanor throughout the call, emphasizing 'momentum' and 'progress' across all business units. CEO David Joyner was particularly emphatic about the company's ability to navigate external challenges, such as regulatory scrutiny and Medicare rate cuts, by focusing on operational execution and the value of their integrated model. The tone shifted to defensive only when addressing the specific headwinds of the Medicare Advantage rate notice, but quickly pivoted back to a narrative of control and advocacy.
Confidence: HIGH - Management reaffirmed full-year 2026 guidance despite significant macro headwinds, citing 'strong momentum' and 'clear line of sight' to improved performance. The specificity of their financial recovery metrics and the early completion of strategic initiatives like CostVantage bolster their credibility.
$7.00 - $7.20
At least $400 billion
At least $9 billion
Hedging & Uncertainty: Management employed hedging primarily around external factors outside their control, such as the Medicare rate notice and regulatory legislation. Phrases like 'simply does not match,' 'disappointing,' and 'remain cautious' were used to describe the environment. However, regarding internal execution, language was definitive and committed: 'commitment... is unchanged,' 'reaffirming our guidance,' and 'confident in our path.' This dichotomy suggests management is confident in its ability to execute operations but is managing investor expectations regarding policy headwinds.
The proposed rate simply does not match the level of medical cost trend in the industry. - J. Joyner, CEO
We are answering those questions with confidence and strong performance. - J. Joyner, CEO
We remain the only entity that sole job is to create the competition and actually negotiate for lower prices on the pharmaceutical supply chain. - J. Joyner, CEO
Our guidance philosophy is predicated on reflecting thoughtful and credible targets while simultaneously striving to identify and execute on opportunities to deliver outperformance. - Brian Newman, CFO
We remain committed to Medicare recovery. We think '25 proved that we've made meaningful progress. - J. Joyner, CEO
Analyst Sentiment: Analysts focused heavily on the sustainability of the Medicare Advantage margin recovery in light of the 2027 rate cuts and the mechanics of the PBM business under regulatory scrutiny. Questions were direct regarding the 'mid-teens growth' target and specific margin trajectories by sub-segment.
Management Responses: Management was defensive but prepared on the MA rate issue, pivoting quickly to 'advocacy' and 'operational discipline.' On the PBM side, Joyner was assertive, framing CVS as the solution to high drug prices. They provided granular details on membership and pricing discipline to reassure investors.
Medicare Advantage 2027 Rate Notice impact on margins and long-term growth targets.
PBM regulatory landscape (FTC investigation, legislation) and the impact on TrueCost adoption.
Aetna margin recovery trajectory and specific performance by sub-segment (MA, Medicaid, Commercial).
Pharmacy & Consumer Wellness performance, specifically script growth and CostVantage impact.
CVS Health is executing a complex turnaround, evidenced by the massive $2.6B swing in Aetna profitability and the stabilization of the retail pharmacy segment. The reaffirmation of 2026 EPS guidance ($7.00-$7.20) despite the disappointing 2027 Medicare rate announcement demonstrates strong operational control and earnings power. However, the 'HOLD' rating reflects the lingering overhang of the Medicare Advantage rate pressure, which creates a headwind for 2027 growth, and the competitive/regulatory risks facing the PBM segment. While the current valuation appears supported by the 2026 targets, visibility into long-term double-digit growth remains clouded by macro-policy risks until the final MA rate is settled.
The 2027 advance rate notice is 'disappointing' and fails to match medical cost trends, posing a risk to payer margins and program sustainability.
Branded manufacturers increased prices by $25 billion in early 2026, outpacing inflation, which CVS argues necessitates strong PBM negotiation power.
CVS views PBM legislation as manageable and aligned with their 'TrueCost' transparency model, potentially accelerating adoption of their preferred business model.